Friday, September 23, 2022

Glenmark Pharma gets approval from Health Canada for nasal spray Ryaltris

Glenmark Pharma gets approval from Health Canada for nasal spray Ryaltris Health Canada granted approval to partner Bausch Health Companies Inc and Glenmark Specialty SA, a subsidiary of the company, for Ryaltris (olopatadine hydrochloride and mometasone furoate nasal spray), Glenmark Pharmaceuticals said in a statement.

from Moneycontrol Business News https://ift.tt/TDb7aLk
at
Labels: , , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

LTIMindtree Q4 Preview: Lower pass-through revenue seen impacting growth marginally

A compilation of estimates suggests the company#39;s Q4 FY24 net profit is projected to decline by 2.2 percent quarter on quarter to Rs 1,1...